US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

PolyPid Ltd. - Ordinary Shares (NQ:PYPD)

5.190 -0.180 (-3.35%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PolyPid Ltd. - Ordinary Shares

An Overlooked Crisis in Hospitals Could Be Pharma’s Next Great Opportunity
Via AB Newswire
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
Via AB Newswire
News headline image
With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval
Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval (NASDAQ:PYPD)* 
Via News Direct
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
PolyPid Ltd. (NASDAQ: PYPD) Near the Top of Equities by Percentage Gain on 1/5
Via Investor Brand Network
News headline image
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025
Via ACCESS Newswire
PolyPid Ltd. (NASDAQ: PYPD) Featured in Coverage of Investor Summit Group’s Q2 Virtual Event
Via Investor Brand Network